Table 3 Multivariable analysis for overall survival in the validation cohort and KIRC

From: A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis

Validation cohort

KIRC

 

HR

95% CI

p-value

 

HR

95% CI

p-value

Sex

Sex

  Female

1

  

  Female

1

  

  Male

0.9

0.4–2.2

0.9

  Male

1.2

0.8–1.8

0.5

Age

Age

   

  <60

1

  

  <60

1

  

  ≥60

0.5

0.2–1.2

0.1

  ≥60

2.0

1.3–3.3

0.002*

Histology

 

  Non clear cell

1

      

  Clear cell

2.1

0.6–7.9

0.3

    

T-stage

T-stage

  1

1

  

  1

1

  

  2

1

0.3–3.0

0.9

  2

0.8

0.4–1.7

0.5

  3

2.7

1.0–7.1

0.04*

  3

2.0

1.2–3.4

0.007*

  4

0.9

0.1–8.8

0.9

  4

2.2

0.6–7.9

0.2

MSKCC

N-stage

  Low

1

  

  0

1

  

  Intermediate

2.9

0.8-3-1

0.05*

  1

2.5

0.9–6.3

0.06

  High

5.3

0.7–3.3

0.021*

    

M-stage

M-stage

  0

1

  

  0

1

  

  1

1.9

0.9–4.1

0.1

  1

3.3

1.9–5.5

0.001*

CD20+B-cells

MS4A1/CD19/PAX5

  Low

1

  

  Low

1

  

  High

2.9

1.4–6.4

0.005*

  High

0.6

0.31–1.3

0.2

  1. *P-value < 0.05 is considered significant
Back to article page